Navigation Links
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Date:5/6/2009

ty, non-fatal stroke, non-fatal myocardial infarction, unstable angina, and a subset of revascularization following the initial event. During the course of the study, patients received therapeutic standard of care in addition to high dose Lipitor (atorvastatin).

In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of sPLA2 activity and mass, clinically meaningful and statistically significant reduction in LDL cholesterol, and a reduction in C-reactive protein.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and heart tracing abnormalities, it is typically classified as a heart attack or myocardial infarction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.┬┐ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family - a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes┬┐ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel┬┐ upstream steps in the inflammation cascade and have the potential to address a variety of diseases. For more information, please visit

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CHESTER, Pa. , Sept. 19, 2014 /PRNewswire/ ... launched two new variable angle plating systems featuring ... technology, surgeons can adapt screw trajectory to match ... towards specific fragments of bone. The systems are ... Foot & Ankle Society (AOFAS) and the International ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... N.J., June 8, 2011 Amerigen Pharmaceuticals Limited ... into a broad-based collaboration agreement regarding the development ... terms of the agreement, AustarPharma will use its ... Amerigen to commercialize in the United States and ...
... ATLANTA, June 8, 2011 Elekta has collaborated with ... NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ... offers Elekta users real-time access to NCCN,s evidence-based clinical ... " The NCCN Guidelines ...
Cached Medicine Technology:Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2
(Date:9/21/2014)... activity benefits of active play, a new study from ... has no goal it is an end in ... with friends, and it represents "an opportunity to experience ... fear, or loneliness." "By focusing on the physical activity ... play that are beneficial to young people,s emotional and ...
(Date:9/21/2014)... Vancouver, BC (PRWEB) September 21, 2014 ... offer educational information to clients in order to help ... initial sessions held at the clinic that will help ... that they can also take active participation in the ... motion, and posture, clients will be able to facilitate ...
(Date:9/21/2014)... September 21, 2014 Over the past ... drugs to inundate the market, thereby cutting into revenue ... industry. According to data from Industry Canada, the loss ... industry $1.8 and $2.5 billion in 2010 and 2012, ... patent exclusivity, which has hampered revenue growth, many pharmaceutical ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... women starting college understand the benefits of a healthy ... they aren,t confident they can follow through on these ... The study involved 268 female college freshmen enrolled ... Eating Right program. The students answered food-related questions such ... were very busy with school work, were very hungry ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News: College Women Can Use Food Strategies, Study Finds 2
... Guttmacher,Institute,s latest report on world abortion rates is ... W. Mosher. The,study, just released today, argues that ... developing countries., Accurate numbers are impossible to ... illegal. Says Mosher: "Neither,Guttmacher nor anyone else knows ...
... Breast Cancer Awareness Month, Premier Partnerships,Promote Breast ... breastcancer.org today,announced several "pink" corporate and retail ... Awareness month in October.,Corporate sponsorships include Campbell ... Baking Company with new retail,partnerships ranging from ...
... VIRGINIA BEACH, Va., Oct. 10 AMERIGROUP,Corporation (NYSE: ... report its earnings,for the third quarter ended September ... 24, 2007. At 9:30 a.m. Eastern Time on ... conference call and webcast,to discuss earnings and other ...
... standard chemo targets HER2-positive tumors , , WEDNESDAY, Oct. 10 ... the drug paclitaxel (Taxol) cuts the recurrence of breast ... form of tumor, a new study finds. , Those ... excess of the protein human epidermal growth factor receptor-2 ...
... Ind. - While biometric equipment is gaining popularity in ... to buildings, industries are finding that many users believe ... germs that could cause illness. , But a Purdue ... surfaces of devices that scan fingerprints or hand geometry ...
... NEW YORK, Oct. 10 The "perfect storm" in ... the incidence of Chronic,Fatigue Syndrome (CFS) and Fibromyalgia (FMS) ... five separate studies. The numbers for those with,CFS in ... re-tallied,at closer to 2.5 million. Previous estimates placed the ...
Cached Medicine News:Health News:PRI Criticizes Guttmacher Report 2Health News:Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org 2Health News:Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org 3Health News:AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 25 2Health News:Drug a New Weapon Against One Form of Breast Cancer 2Health News:Drug a New Weapon Against One Form of Breast Cancer 3Health News:Biometric sensors no dirtier than doorknobs, study finds 2Health News:Biometric sensors no dirtier than doorknobs, study finds 3Health News:'From Fatigued to Fantastic!' Provides Antidote to Energy Crisis 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: